Burning Rock (BNR) Q4 2022: Pharma Revenue Surges 200% as MRD, Early Detection Drive Multi-Year Growth Path

March 28, 2023 | By EarningsIQ Research

BNR’s Q4 and full-year results highlight a strategic pivot toward profitability and operational discipline, with a 200% surge in pharma revenue and expanding MRD traction underpinning a multi-year growth runway. Management is prioritizing break-even (ex-R&D) in 2023, while investing in multi-cancer early detection and scaling in-hospital MRD deployments. Investors should watch for execution on hospital channel expansion and regulatory wins as BNR navigates a maturing precision oncology market in China.

Summary

• Pharma Backlog Execution Accelerates: Pharma services revenue soared over 200% on robust contract delivery.
• MRD and In-Hospital Model Gain Traction: Personalized MRD launches and hospital installs set up new volume engines.
• Profitability Focus Tightens: Cost discipline and SG&A reductions put break-even (ex-R&D) within reach for 2023.

Business Overview

Burning Rock (BNR) is a precision oncology company specializing in NGS (next-generation sequencing)-based cancer diagnostics. The business spans three segments: therapy selection (tissue and liquid biopsy tests for guiding cancer treatment), MRD (minimal residual disease) testing (detecting cancer recurrence), and multi-cancer early detection (MCED) (screening for multiple cancers in asymptomatic populations). BNR serves hospitals, pharmaceutical companies, and consumers, generating revenue through clinical testing, pharma services, and product sales.

Performance Analysis

BNR finished Q4 ahead of internal expectations, with revenue down just 3% YoY despite a challenging COVID backdrop and sharp volume drops in December and January. Full-year 2022 revenue grew 11% YoY, which management believes is at the high end of the precision oncology sector in China. The standout was the pharma services segment, which delivered over 200% revenue growth on the back of a 43% increase in new contract value, driven by strong backlog execution and international demand.

Therapy selection, the company’s core business, saw 13% volume growth for the year, anchored by the in-hospital channel and the approval of a nine-gene panel by NIMPA, China’s medical regulator. The newly launched MRD product, BR-PROFIT, is scaling rapidly, with increasing patient volumes and early clinical data supporting multi-cancer utility. Adjusted gross profit (ex-depreciation/amortization) grew 12% YoY, while all three OPEX lines declined in Q4, reflecting aggressive cost optimization and a 25% reduction in headcount.

• Pharma Revenue Outperformance: Pharma segment outpaced overall growth, signaling strong execution and global demand.
• Core In-Hospital Channel Strength: In-hospital therapy selection volumes expanded, reinforcing BNR’s leading market position.
• Cost Structure Reset: SG&A and R&D discipline drove OPEX down, narrowing the gap to break-even (ex-R&D).

Despite pandemic headwinds and a Q1 volume trough, BNR returned to positive YoY growth in February and enters 2023 with a healthy cash position and a clear path to profitability, contingent on sustained execution in core and emerging segments.

Executive Commentary

Strategic Positioning

1. Pharma Services Scale-Up

Pharma services, BNR’s business unit supporting pharmaceutical companies with clinical testing and companion diagnostics, delivered a >200% revenue increase and 43% growth in new contract value. This surge reflects robust backlog execution and an expanding international footprint, positioning pharma as a durable growth engine and margin lever.

2. In-Hospital Model Expansion

In-hospital therapy selection, BNR’s core channel, remains the primary driver of volume and revenue. The company’s ability to secure NIMPA approvals for its NGS panels and deepen penetration in top-tier hospitals solidifies its leadership in China’s precision oncology market. Management is focused on improving sales productivity and hospital contracting, especially as MRD installations ramp up.

3. MRD and Early Detection Innovation

MRD (minimal residual disease), a new diagnostic paradigm for cancer recurrence monitoring, is scaling rapidly for BNR. The BR-PROFIT personalized MRD product is being installed in leading hospitals, with clinical data across lung, colon, and pancreatic cancer supporting its utility. Meanwhile, multi-cancer early detection (MCED) R&D is prioritized, with ongoing trials (PREVENT, PREDICT, PRESENT) and an FDA breakthrough device designation for the six-cancer test, signaling future regulatory and commercial upside.

4. Profitability and Cost Discipline

Cost optimization, including a 25% headcount reduction and OPEX cuts, is central to BNR’s 2023 plan. The company targets break-even (excluding R&D) within the year, with a focus on SG&A efficiency and selective R&D investment in MCED. Cash runway of three years provides stability for continued R&D and commercial expansion.

Key Considerations

This quarter marks a transition period for BNR, as the company balances aggressive growth in new business lines with a disciplined push toward profitability and operational focus.

Key Considerations:

• MRD Commercialization Milestones: Successful in-hospital MRD installations and clinical readouts will be critical for volume and market adoption.
• Pharma Segment Durability: Sustaining triple-digit pharma revenue growth will depend on backlog execution and continued international demand.
• Regulatory Pathways: FDA and NIMPA approvals for new panels and MCED products are pivotal for long-term market expansion.
• Cost Management: Maintaining SG&A and R&D discipline is essential to achieve break-even and fund innovation without diluting shareholders.

Risks

BNR faces execution risk in scaling MRD and MCED commercialization, particularly as hospital contracting and physician education remain bottlenecks. Macro headwinds, including COVID-related volume shocks and regulatory uncertainty, could disrupt growth trajectories. Heavy R&D investment in MCED, if not matched by commercial uptake, may pressure margins and delay profitability. Competitive intensity in China’s precision oncology market is rising, increasing the need for differentiation and regulatory progress.

Forward Outlook

For Q1 2023, BNR guides for:

• Moderate expectations due to a sharp January volume decline (Jan-Feb combined volumes down 28% YoY)
• Return to positive YoY growth as of February

For full-year 2023, management targets:

• Break-even (ex-R&D) in at least one quarter
• 20% revenue growth

Management flagged:

• Prioritization of profitability and cost control, especially in SG&A
• MRD in-hospital model to drive incremental growth in Q4 2023

Takeaways

BNR’s results show a company in strategic transition, leveraging pharma outperformance and MRD innovation to offset pandemic disruptions and position for sustainable growth.

• Pharma and MRD Outperformance: These segments are now the primary growth levers, with pharma’s 200% surge and MRD’s hospital installs underpinning future revenue streams.
• Cost Reset and Profitability Focus: Aggressive headcount and OPEX reductions align with a credible plan to reach break-even (ex-R&D) in 2023, providing a margin of safety for continued investment in MCED.
• Execution Watchpoints: Investors should monitor MRD commercialization milestones, regulatory wins, and the pace of hospital channel expansion for confirmation of the multi-year growth thesis.

Conclusion

BNR’s Q4 and 2022 performance reinforce its evolving business model, with pharma and MRD growth offsetting legacy headwinds and a disciplined march toward profitability. The company’s ability to deliver on hospital channel expansion and regulatory progress will determine the next leg of value creation.

Industry Read-Through

BNR’s pharma revenue surge and MRD adoption reflect a broader shift in China’s precision oncology market toward integrated diagnostics and companion testing, with regulatory clarity (NIMPA, FDA) now a key differentiator. The focus on in-hospital models and early detection mirrors global trends, suggesting that scale, clinical data, and regulatory approvals will separate winners from laggards. Competitors in the sector must accelerate hospital penetration, invest in multi-cancer R&D, and demonstrate cost discipline to remain viable as the market matures and reimbursement frameworks evolve.

BNR Healthcare Diagnostics Pharma Services Precision Oncology MRD Early Detection Profitability